A trial of gerilimzumab in China

Trial Profile

A trial of gerilimzumab in China

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Gerilimzumab (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions
  • Sponsors Genor Biopharma
  • Most Recent Events

    • 11 Jan 2017 New trial record
    • 24 Dec 2016 According to a Genor Biopharma media release, the company has received clinical trial approval from the China Food and Drug Administration (CFDA) for gerilimzumab.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top